BRISTOL-MYERS SQUIBB COMPANY

Official Publications Bristol-Myers Squibb Company Borsa Italiana

Equities

4BMY

US1101221083

Real-time Estimate Tradegate Other stock markets 15:32:24 03/07/2024 BST			5-day change	1st Jan Change
37.26 ^EUR	-1.74%		-3.99%	-18.29%

07-02	Cartesian Therapeutics, Inc. Appoints Kemal Malik to its Board of Directors	CI
07-01	Bristol-Myers Squibb to Pay $2.7 Million to Settle Potential Anti-Competition Case, Israeli Agency Says	MT

Official Publications

SEC Filing 10Q-1	26/04/23	CO
Slide show Q1	26/04/23	CO
1st quarter results	26/04/23	CO
Annual Report	26/04/23	CO
SEC Filing 8K	26/04/23	CO
SEC Filing 8K	25/04/23	CO
Proxy Statments	22/03/23	CO
SEC Filing 10K	13/02/23	CO
Slide show results	01/02/23	CO
Annual results	01/02/23	CO
SEC Filing 8K	01/02/23	CO
SEC Filing 8K	30/01/23	CO
SEC Filing 8K	08/01/23	CO
Slide show Q3	25/10/22	CO
3rd quarter results	25/10/22	CO
SEC Filing 10Q-2	25/10/22	CO
SEC Filing 8K	25/10/22	CO
SEC Filing 8K	26/07/22	CO
SEC Filing 10Q-2	26/07/22	CO
1st-half-year results	26/07/22	CO
Slide show half-year results	26/07/22	CO
SEC Filing 4K	15/06/22	CO
SEC Filing 8K	14/06/22	CO
Dividends	14/06/22	CO
Slide show Q1	28/04/22	CO

1 2 3

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 06:06 pm

Our Free Content Help you Secure and Increase the Performance of Your Investments

Securing my Investments

fermer